DPD Testing Guides Chemotherapy Dosing

Taylor Sweka, Faculty of Medicine, Aalborg University, Denmark, presents a study examining the clinical impact of pretreatment DPD testing in patients receiving fluoropyrimidine-based chemotherapy. In a cohort of over 1,400 patients, genotyping more consistently guided dose reductions compared with plasma uracil measurements, while treatment decisions also depended on patient condition and comorbidities. Although the study found a low incidence of severe toxicity, limiting conclusions on clinical impact, the results highlight the role of pharmacogenetic testing in personalizing chemotherapy dosing.